Rapid Response Team to focus on countering potential threat of pandemic flu in the United States
In response to the emerging threat of pandemic (avian) influenza, FDA has announced the formation of a Rapid Response Team to ensure that antiviral drugs are available to citizens in the United States if they are needed. While avian flu has not emerged in this country, the team will help ensure an adequate supply of treatments, such as oseltamivir (Tamiflu, Roche) and other anti-influenza drugs, for stockpiling in the event there is an outbreak in the United States.
In response to the emerging threat of pandemic (avian) influenza, FDA has announced the formation of a Rapid Response Team to ensure that antiviral drugs are available to citizens in the United States if they are needed. While avian flu has not emerged in this country, the team will help ensure an adequate supply of treatments, such as oseltamivir (Tamiflu, Roche) and other anti-influenza drugs, for stockpiling in the event there is an outbreak in the United States.
"Making sure Americans are protected against an outbreak of avian flu is one of FDA's top priorities," said Andrew C. von Eschenbach, MD, acting FDA commissioner. "Using the Rapid Response Team approach, we believe we could review a complete drug application in 6 to 8 weeks."
In partnership with the Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and industry, the Rapid Response Team will work to ensure that necessary measures are taken to provide an adequate and timely supply of antiviral drugs to treat avian flu, if it should emerge in the United States.
Partnering with industry, academia, and other government agencies, the team will support the design and conduct of clinical studies to test new potential treatments for avian influenza.
In the event of a pandemic, such new medications could be made available under Emergency Use Authorization. In addition, the team will facilitate the development and availability of safe and effective vaccines that could help protect Americans against a future pandemic, including avian flu. These efforts include measures to help increase vaccine manufacturing capacity and production of currently licensed vaccines using avian flu strains, and facilitating and evaluating studies that use new technologies.
As the threat of pandemic flu emerges as a public health concern, FDA anticipates an increase in the sale of counterfeit or fraudulent treatments. Presently, the agency is not aware of any counterfeit oseltamivir cases in the United States; however, there are initiatives in place to deter counterfeiters and other parties who sell counterfeit products that they say can prevent or treat avian flu.
FDA will continue to work with stakeholders in the US drug distribution system to strengthen the safety and security of the domestic drug supply and will continue to:
The FDA Counterfeit Alert Network is ready and available to help disseminate information in the event of counterfeit incidents. The Counterfeit Alert Network is a partnership between FDA and numerous organizations that have agreed to distribute FDA-approved messages to their members about counterfeits on a timely basis to assure rapid action to minimize the risk of exposure to counterfeit products.
In the event of a confirmed counterfeit case in the United States, FDA will also send an alert to these partners. FDA will send out an FYI notice to partners if a counterfeit incident is confirmed elsewhere in the world that could affect US patients.
To minimize the risk of counterfeit or fraudulent flu treatments, FDA recommends the following:
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
